Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
enasidenib (idhifa) (1 trial)
ruxolitinib (jakafi) (1 trial)
Blast Crisis (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasms (Phase 2)
Primary Myelofibrosis (Phase 2)
Trials (1 total)
Trial APIs (2 total)